FHA
RIGL icon

Flagship Harbor Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Flagship Harbor Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-300
Closed -$12.8K – 1851
2025
Q4 		$12.8K Buy
+300
New +$11.3K ﹤0.01% 1444
2024
Q2 		– Sell
-1,000
Closed -$14.8K – 719
2024
Q1 		$14.8K Hold
1,000
– – ﹤0.01% 673
2023
Q4 		$14.5K Hold
1,000
– – ﹤0.01% 621
2023
Q3 		$10.8K Hold
1,000
– – ﹤0.01% 604
2023
Q2 		$12.9K Hold
1,000
– – ﹤0.01% 613
2023
Q1 		$13.2K Buy
+1,000
New +$15.9K ﹤0.01% 614

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Flagship Harbor Advisors's RIGL Position: Q1 2026 in Review

Flagship Harbor Advisors sold out of Rigel Pharmaceuticals (RIGL) in Q1 2026, closing a stake of 300 shares — an estimated $12.8K sold.

Flagship Harbor Advisors first reported a position in RIGL in Q1 2023 and held it in 6 quarters. The position peaked at $14.8K in Q1 2024. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • Flagship Harbor Advisors reported no remaining Rigel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Flagship Harbor Advisors sold 300 Rigel Pharmaceuticals shares in Q1 2026, an estimated $12.8K.
  • Flagship Harbor Advisors first reported a position in Rigel Pharmaceuticals in Q1 2023 and held it in 6 quarters.
  • Flagship Harbor Advisors's Rigel Pharmaceuticals position peaked at $14.8K in Q1 2024.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Flagship Harbor Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.